The coronavirus disease-2019 (COVID-19) pandemic continues to be a cause of unprecedented global morbidity and mortality. Whilst COVID-19 vaccination has emerged as the only tangible solution to reducing poor clinical outcomes, vaccine hesitancy continues to be an obstacle to achieving high levels of vaccine uptake. This represents particular risk to patients with autoimmune diseases, a group already at increased risk of hospitalization and poor clinical outcomes related to COVID-19 infection. Whilst there is a paucity of long-term safety and efficacy data of COVID-19 vaccination in patients with autoimmune diseases, the current evidence strongly suggests that the benefits of vaccination outweigh the risks of adverse effects and disease flares. Herein, we report the protocol of the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study, an ongoing international collaborative study involving 29 countries and over 110 investigators.
COVID-19 vaccination in autoimmune disease (COVAD) survey protocol / Sen, P.; Gupta, L.; Lilleker, J. B.; Aggarwal, V.; Kardes, S.; Milchert, M.; Gheita, T.; Salim, B.; Velikova, T.; Gracia-Ramos, A. E.; Parodis, I.; O'Callaghan, A. S.; Nikiphorou, E.; Tan, A. L.; Cavagna, L.; Saavedra, M. A.; Shinjo, S. K.; Ziade, N.; Knitza, J.; Kuwana, M.; Cagnotto, G.; Nune, A.; Distler, O.; Chinoy, H.; Aggarwal, V.; Aggarwal, R.; Barman, B.; Singh, Y. P.; Ranjan, R.; Jain, A.; Pandya, S. C.; Malaviya, A. N.; Pilania, R. K.; Sharma, A.; Manoj, M. M.; Gupta, V.; Kavadichanda, C. G.; Patro, P. S.; Ajmani, S.; Phatak, S.; Goswami, R. P.; Chowdhury, A. C.; Mathew, A. J.; Shenoy, P.; Asranna, A.; Bommakanti, K. T.; Shukla, A.; Naveen, R.; Cansu, D. U.; Pauling, J. D.; Wincup, C.; Chatterjee, T.; Kim, M.; Giannini, M.; Del Papa, N.; Sambataro, G.; Fabiola, A.; Govoni, M.; Parisi, S.; Bocci, E. B.; Sebastiani, G. D.; Fusaro, E.; Sebastiani, M.; Quartuccio, L.; Franceschini, F.; Sainaghi, P. P.; Orsolini, G.; De Angelis, R.; Danielli, M. G.; Traboco, L. S.; Wibowo, S. A. K.; Serrano, J. R.; La Torre, I. G. -D.; Tehozol, E. A. Z.; Loarce-Martos, J.; Prieto-Gonzalez, S.; Gil-Vila, A.; Aranega, R.; Nakashima, R.; Sato, S.; Kimura, N.; Kaneko, Y.; Tomaras, S.; Gromova, M. A.; Aharonov, O.. - In: RHEUMATOLOGY INTERNATIONAL. - ISSN 1437-160X. - 42:1(2022), pp. 23-29. [10.1007/s00296-021-05046-4]
COVID-19 vaccination in autoimmune disease (COVAD) survey protocol
Sebastiani M.;
2022
Abstract
The coronavirus disease-2019 (COVID-19) pandemic continues to be a cause of unprecedented global morbidity and mortality. Whilst COVID-19 vaccination has emerged as the only tangible solution to reducing poor clinical outcomes, vaccine hesitancy continues to be an obstacle to achieving high levels of vaccine uptake. This represents particular risk to patients with autoimmune diseases, a group already at increased risk of hospitalization and poor clinical outcomes related to COVID-19 infection. Whilst there is a paucity of long-term safety and efficacy data of COVID-19 vaccination in patients with autoimmune diseases, the current evidence strongly suggests that the benefits of vaccination outweigh the risks of adverse effects and disease flares. Herein, we report the protocol of the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study, an ongoing international collaborative study involving 29 countries and over 110 investigators.Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris